Results 221 to 230 of about 65,998 (238)

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2020
Jessica Hassel, Ralf Gutzmer, Elisabeth Livingstone   +2 more
exaly  

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity

ESMO Open, 2018
Dong-Wan Kim, Dae Seog Heo, Tae Min Kim
exaly  

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Journal of Thoracic Oncology, 2019
VÍCTOR Moreno, Anna Farago, Matthew Hellmann   +2 more
exaly  

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Journal of Hepatology, 2020
Jaclyn Neely, Joong-Won Park, Ignacio Melero   +2 more
exaly  

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

European Journal of Cancer, 2019
R H J Mathijssen, Joachim Aerts, Stefan Sleijfer   +2 more
exaly  

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Lancet, The, 2017
Tae-You Kim, Jaclyn Neely, Winnie Yeo
exaly  

<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients</p>

Therapeutics and Clinical Risk Management, 2019
Haijun Zhang
exaly  

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

Nature Reviews Clinical Oncology
openaire   +2 more sources

Nivolumab

Reactions Weekly, 2022
openaire   +1 more source

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Neuro-Oncology, 2018
David Reardon, Joachim Baehring, John Sampson   +2 more
exaly